News General

De-risking new immunoassay development

September 21, 2021 12:00 PM

How Werfen is driving immunoassay development

In vitro diagnostics are playing a significant role in current healthcare systems and our partners must provide practitioners and their patients with innovative, reliable, and high-quality immunoassays in a sustainable and efficient way.

At Werfen we work alongside our partners to expand their immunoassay portfolio by de-risking their novel developments and reducing time-to-market.

We work towards moving your immunoassay portfolio one step further

At the outset of a project, we discuss and design jointly with our partners the assay development business model that best suits their needs. We have a dedicated R&D team who works from the inception and characterization of the biomaterial to the clinical validation of the new immunoassay.

We rely on our R&D Core Technologies team whose objective is to de-risk the new immunoassay development at the initial stages of new assay formulations to reduce risks and uncertainties from the outset of the project.

The strategy of the R&D Core Technologies team is built around four pillars:

Strategy of the R&D Core Technologies team to de-risk new developments

We at Werfen advance our shared objective by providing our partners with a new immunoassay to expand their portfolio in a quality and timely manner. 

Click here for some examples, including a practical case of an immunoassay to detect a hormone in the Werfen Webinar - OEM Series: De-risking immunoassay development.

Share Press Release:

LinkedIn twitter facebook

Contact us

Please contact us directly via telephone or with the following form.

Tel. +34 93 860 90 00


Biokit, S.A. and Biokit Research & Development, S.L.U. will process your personal data to respond to your requests for information or support, or to understand your needs and provide you with a better service relying on our legitimate interest to do so. You can find more information about our data privacy practices and how to exercise your rights in our Privacy Policy. You can also contact us at